The prospective study reportedly showed an improvement of over 10%.
Stock.adobe.com
Lunit announced the results of a prospective study that looked into the usage of AI in mammography screening.1 According to the results, the powerful technology improves the detection rates for breast cancer without increasing recall rates. In a press release, Lunit states that AI improved the detection rates by 13.8%.
The study’s lead and corresponding author Professor Chang explained, “This prospective study offers compelling real-world evidence that AI can improve early cancer detection while maintaining effectiveness and reducing unnecessary patient anxiety caused by false positives in a single-reading setting.”
Lunit is an AI company that develops solutions for cancer diagnostics and therapeutics.
In the same press release, Lunit’s CEO Brandon Suh said, “This latest prospective study in South Korea further solidifies Lunit INSIGHT MMG's potential as an indispensable tool in breast cancer screening. Whether in a single-reader or double-reader setting, AI can serve as a powerful force multiplier, assisting radiologists in detecting cancer earlier and more accurately."
Suh continued, “As AI adoption accelerates, we remain committed to driving innovation and making AI-powered cancer screening the new standard of care," added Suh. "By working closely with healthcare providers worldwide, we aim to ensure that AI benefits as many patients as possible."
Lunit also recently announced that it has reached a new agreement with Cloud Solutions, part of Saudi Arabia’s largest medical group, to supply it’s AI-powered X-ray analysis solution to the region for the next three years.2 The two organizations had previously collaborated in 2023.
In a press release, Suh said, “We are proud to further strengthen our collaboration with Dr. Sulaiman Al Habib Medical Group. This second contract underscores the value of our AI solutions and reflects our shared commitment to advancing healthcare through innovation."
Suh continued, “Expanding our partnership with HMG demonstrates the growing demand for AI-powered diagnostics across the Middle East. We are excited to continue supporting Saudi Arabia's healthcare transformation while addressing key challenges such as radiologist shortages."
Lunit also recently announced the appointment of Craig Hadfield as CEO of one its subsidiaries, Volpara Health Technologies.3 In a press release, Suh said, “We are confident that Craig's leadership will drive Volpara's continued success and innovation in breast health. His deep understanding of Volpara's business and his proven leadership make him the ideal person to guide the company into its next phase of growth. We look forward to his continued success in driving Volpara's mission to advance breast health solutions worldwide."
In the same press release, Hadfield added, “I am honored to step into this role and continue leading Volpara's mission to transform breast health through innovative AI-powered solutions. Having been part of Volpara's journey for nearly a decade, I look forward to working with our talented team, partners, and customers to expand our impact and drive even greater value in breast cancer detection and patient care."
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
The 8 Market Access Performance Metrics You Should Be Tracking
March 25th 2025This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.